Biologic Response Modifiers in the Treatment of Gastrointestinal Malignancies

References

• Reed K, Vose P C, Jursffer B S. Pancreatic cancer: 30 year review (1947–1977). Am J Surg 1979; 138: 929–933
   PubMed Web of Science ®Google Scholar
• Appelqvist P, Virer H, Minkinen J, Kajanti M, Kostianin S, Rissanen P. Operative finding, treatment, and prognosis of carcinoma of the pancreas. An analysis of 267 cases. J Surg Oncol 1983; 23: 143–150
   PubMed Web of Science ®Google Scholar
• Higgins G, Humphrey E, Juler G, Leveen H, McCaughan J. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. Cancer 1976; 38: 1461–1467
   PubMed Web of Science ®Google Scholar
• Koprowski H, Steplewski Z, Mitchall K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957–971
   PubMedGoogle Scholar
• Blaszyk-Thurin M, Thurin J, Hindsgaul O, Karlsson K A, Steplewski Z, Koprowski H. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem 1987; 262: 372–379
   PubMed Web of Science ®Google Scholar
• Ross A H, Herlyn D, Diopoulos D, Koprowski H. Isolation and characterization of a carcinoma-associated antigen. Biochem Biophys Res Commun 1986; 135: 297–303
   PubMed Web of Science ®Google Scholar
• Ansson M JE, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structures of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834: 110–117
   PubMedGoogle Scholar
• Hellström I, Horn D, Linsley P, Brown J P, Bran-Kovan V, Hellström K-E. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 1986; 46: 3917–3923
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Sears H F, Mattis J, Herlyn D, Hayry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1: 762–765
   PubMed Web of Science ®Google Scholar
• Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma specific antigen. Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76: 1438–1452
   PubMed Web of Science ®Google Scholar
• Frodin J-E, Harmenberg U, Biberfeld P, Chris-Tensson B, Lefvert A-K, Rieger A, Shetye J, et al. Clinical effects of monoclonal antibodies (MAb 17–1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988; 7: 309–321
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Frodin J-E, Ragnhammar P, Masucci G, Shetye J, Christensson B, Biberfeld P, et al. The clinical use of monoclonal antibodies, MAb 17–1A, in the treatment of patients with metastatic colorectal carcinoma. Med Oncol Tumor Phar-macother 1989, (in press)
   Google Scholar
• Adams D O, Hull T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype contain increased numbers of macrophages activated for a distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA 1984; 81: 8506–3510
   Web of Science ®Google Scholar
• Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H. Mechanisms of tumor growth inhibition. Hybridoma 1986; 5: 59–64
   Google Scholar
• Shetye J, Frodin J-E, Christensson B, Grant C, Jacobson, Sundelius S, Sylvten M, et al. Immu-nohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17–1A). Cancer Immunol Immu-nother 1988; 27: 154–162
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Frodin J-E, Christensson B, Shetye J, Biberfeld P, Lefvert A-K, Pihlstedt P, . Application of monoclonal antibodies (MAb 17–1A) in the treatment of colorectal carcinomas. Monoclonal antibodies in clinical oncology, R A Carrano, J Y Doullard, et al. Marcel Dekker Inc., New York 1988, (in press)
   Google Scholar
• Mellstedt H, Frodin J-E, Masucci G, Lindemalm C, Weldelin C, Christensson B, Shetye J, . MAb 17–1A used for therapy of patients with metastatic colorectal carcinomas. New approaches in cancer treatment, H G Berger, R Reisfeld, et al. Springer Verlag, Berlin 1988, (in press)
   Google Scholar
• Mellstedt H, Frödin J-E, Masucci G, Lindemalm C, Wedelin C, Christensson B, Shetye J, et al. Monoclonal antibodies (MAb 17–1A) for the treatment of patients with metastatic colorectal carcinomas. Acta Chir Scand 1988, (in press)
   Google Scholar
• Masucci G, Lindemalm C, Frödin J-E, Hagström B, Mellstedt H. Effect of human blood mononuclear cell populations in antibody dedpendent cellular cytotoxicity (ADCC) using two murine (CO17–1A and Br55–2) and one chimeric (17–1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hvbridoma 1988; 7: 429–440
   PubMedGoogle Scholar
• Jerne N K. Towaids; network theory of the immune system. Ann Immunol (Paris) 1974; 125: 373–389
   Google Scholar
• Herlyn D, Sears H, Iliopoulos D, Lubeck M, Dou-Illard J-Y, Sindelar W, Tempero M, et al. Anti-idiotypic antibodies to monoclonal antibody CO17–1A. Hybridoma 1986; 5: 51–58
   PubMedGoogle Scholar
• Steinitz M, Tamir S, Pizov G, Frodin J-E, Lefvert A-K, Mellstedt H. Human monoclonal anti-idio-typic antibodies. I. Establishment of immortalized cell lines from tumor patient treated with mouse monoclonal antibodies. J Immunol 1988; 141: 3516–3522
   PubMed Web of Science ®Google Scholar
• Janson C H, Frödin J-E, Masucci G, Wigzell H, Mellstedt H. Intravenous infusions of mouse monoclonal antibodies (MAb 17–1A) using different dosage schedules. Plasmapharmacokinetics, serum immune reactivity, antibody induction and side effects. Mechanisms of action and therapeutic applications of biologicals in cancer and immune deficiency disorders, UCLA symposia, Denver, Colorado. Alan R. Liss Inc, New York 1988, (in press)
   Google Scholar
• Pimm M W, Baldwin R W. Localization of an anti-tumor monoclonal antibody in human tumor xen-ographs: kinetic and quantitative studies with the 791T/36 antibody. Monoclonal antibodies for cancer detection and therapy, R W Baldwin, V S Byers. Academic Press, New York 1985; 97–128
   Google Scholar
• Bengmark S, Hafström L O. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinomas by laparotomy. Cancer 1969; 23: 198–202
   PubMed Web of Science ®Google Scholar
• Bedikian A Y, Chen T T, Malahy M-A, Patt Y Z, Bodey G P. Prognostic factors influencing survival of patients with advanced colorectal cancer. Hepatic artery infusion versus systemic intravenous chemotherapy for liver metastases. J Clin Oncol 1984; 2: 174–180
   PubMed Web of Science ®Google Scholar
• Verill H, Goldberg M, Rosenbaum R, Abbot R, Simunovic L, Steplewski Z, Koprowski H. Clinical trial of Wistar Institute 17–1A monoclonal antibody in patients with advanced gastroinestinal aden-ocarcinoma: a preliminary report. Hybridoma 1986; 5: 175–183
   Google Scholar
• Weiner L M, Steplewski Z, Koprowski H, Sears H, Litwin S, Comis R L. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17–1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986; 5: 65–77
   PubMedGoogle Scholar
• Sears H F, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910–5913
   PubMed Web of Science ®Google Scholar
• Weiner L M, Moldofsky P J, Gatenby R A, O'Dwyer J, O'Brien J, Litwin S, Comis R L. Antibody delivery and effector cell activation in a phase II trial of recombinant γ-interferon and the murine monoclonal antibody CO17–1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568–2573
   PubMed Web of Science ®Google Scholar
• LoBuglio A F, Saleh M N, Lee J, Khazaeli M B, Carrano R, Holden H, Wheeler R H. Phase I trial of multiple large doses of murine monoclonal antibody CO17–1A. I. Clinical aspects. J Natl Cancer Inst 1988; 80: 932–936
   PubMed Web of Science ®Google Scholar
• Drew S I, Terasaki P I, Johnson C, Chia D, Wakisaka A, Hardiwidjaja S, Ciccairelli J, . Phase I study of high-dose serotherapy with cytotoxic monoclonal antibodies in patients with gastrointestinal malignancies. Monoclonal antibodies, S N Chatterjee, et al. PSG Publishing Co., Littleton, MassUSA 1985; 127–136
   Google Scholar
• Tempero M A, Pour P M, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17–1A and leukopheresis in immunotherapy of pancreatic cancer. Hybridoma 1986; 5: 133–138
   Google Scholar
• Sindelar W F, Maher M M, Herlyn D, Sears H F, Steplewski Z, Koprowski H. Trial of therapy with monoclonal antibody 17–1A in pancreatic carcinoma: preliminary results. Hybridoma 1986; 5: 125–132
   Google Scholar
• Paul A R, Enstrom P F, Weiner L M, Steplewski Z, Koprowski H. Treatment of advanced measurement or evaluable pancreatic carcinoma with 17-A1 murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mito-mycin (FAM). Hybridoma 1986; 5: 171–174
   PubMed Web of Science ®Google Scholar
• Schulz G, Muhrer K H, Klapdor R, Kübel R, Harthus H P, Madry N, Bosslet K. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494. Int J Cancer 1988; 89–94, (suppl 2)
   Google Scholar
• Douillard J Y, Lehur P A, Vignoud J, Blottiére H, Maurec C, Thedrez P, Kremer M, et al. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma 1986; 5: 139–149
   Google Scholar
• Lillis P K, Brown T D, Beogher K, Koeller J, Marcus S G, von Hoff D D. Phase II trial of recombinant beta interferon in advanced colorectal cancer. Cancer Treat Rep 1987; 10: 965–967
   Google Scholar
• Clark P I, Slevin M L, Reznek R H, Niederle N, Kurschel E, Lundell G, Cedermark B, et al. Two randomized phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-Fluoro-uracil (trial 2) in advanced colorectal cancer. Int J Color Dis 1987; 1: 26–29
   Google Scholar
• Krown S E, Mintzer D, Cunningham-Rundles S, Niedzwiecki D, Krim M, Einzig A I, Gabrilove J L, et al. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat Rep 1987; 1: 39–45
   Google Scholar
• Eggermont A M, Weimar W, Tank B, Dekkers-Bijma A M, Maraquet R L, Lameris J S, Westbroek D L, et al. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (RIFN alpha A). Cancer Immunol Immunother 1986; 1: 81–84
   Google Scholar
• O'Connel M J, Moertel C G, Schutt A J, Sherwin S A. Phase II clinical trial of human recombinant gamma interferon (RIFN-gamma) in patients (PTS) with advanced colorectal cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1986; 27: 181
   Google Scholar
• Medenica R, Slack N. Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 1985; 1: 53–76
   Google Scholar
• Flodgren P, Hugander A, Sjögren H O. Recombinant leukocyte a interferon as single agent therapy or in combination with cimetidine in patients with advanced colorectal carcinoma. A phase II investigation. Acta Radiol Oncol 1985; 1: 25–34
   Google Scholar
• Lundell G, Blomgren H, Cedermark B, Silfverswärd C, Theve T, Ohman U. High dose rDNA human alpha-2 interferon therapy in patients with advanced colorectal adenocarcinoma: phase II study. Radiother Oncol 1984; 4: 325–332
   Google Scholar
• Siligals R M, Ahlgren J D, Neefe J R, Rothman J, Rudnick S, Galicky F P, Schein P S. A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 1984; 10: 2257–2261
   Google Scholar
• Kirkwood J M, Ernstoff M S. Interferons in the treatment of human cancer. J Clin Oncol 1984; 4: 336–352
   Google Scholar
• Oberg K, Eriksson B, Norheim I. Interferon treatment of neuro-endocrine tumors of pancreas and gut. Clinical aspects of interferons, M Revel. Kluwer Academic Publishers, Boston 1988; 195–212
   Google Scholar
• Urba W J, Clark J W, Longo D L, Smith J W, Miller R, Kopp W C, Finch L, et al. Phase I evaluation of the toxicity and immunomodulating effects of tumor necrosis factor (TNF) and interferon gamma (IFN-γ). Proc Annu Meet Am Soc Clin Oncol 1988; 7: A641
   Google Scholar
• Schwartz J, Hersh E M, Wiggins C, Scuderi P. Phase I study of recombinant tumor necrosis factor (r-TNF) administered by continuous infusion to cancer patients. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A220
   Google Scholar
• Rosenberg S A, Lotze M T, Muul L M, Chang A E, Avis F P, Leitman S, Lineham W M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 879–897
   PubMed Web of Science ®Google Scholar
• West W H, Tauer K W, Yannelli J R, Marshall G D, Orr D W, Thurman G B, Oldham R K. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 897–898
   Web of Science ®Google Scholar
• Sano T, Ischizuya Y, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Tamura T, et al. Phase I trial of recombinant interleukin-2 (RIL-2) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1987; 6: A953
   Google Scholar
• Steis R, Bookman M, Clark J, Urba W, McKnight J, Smith J, Schoeberger C, et al. Intraperitoneal lymphokine activated killer (LAK) and interleukin-2 (IL-2) therapy for peritoneal carcinomatosis: toxicity, efficacy and laboratory results (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1987; 6: A984
   Google Scholar
• Paciucci P A, Bhardwaj S, Odchimar R, Glidewell O, Holland J F. Immunotherapy for metastatic cancer with recombinant interleukin-2 (rIL2) by continuous infusion with and without adoptive cell transfer. Proc Annu Meet Am Soc Clin Oncol 1988; 7: A630
   Web of Science ®Google Scholar
• Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedei I, Dreikhausen U, Raab R, et al. Anti-idiotype immunization of cancer patients: modalities of the immune response. Proc Natl Acad Sci USA 1987; 84: 8055–8059
   PubMed Web of Science ®Google Scholar
• Vanky F, Klein E, Willems J, Book K, Ivert T, Péterffy A, Nilssone U, et al. Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Cancer Immunol Immunother 1986; 21: 69–76
   PubMed Web of Science ®Google Scholar
• Wunderlich M, Schiessel R, Rainer H, Rauhs R, Kovats E, Schemper M, Dittrich D C, et al. Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg 1985; 107–110, suppl
   Web of Science ®Google Scholar
• Bhattacharya-Chatterjee M, Pride M W, Seon B K, Kohler H. Idiotype vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes. J Immunol 1987; 139: 1354–1360
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Saeki Y, Chen J J, Köhler H. Analysis of the idiotypoc network in tumor immunity. J Immunnol 1987; 139: 3902–3910
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Saeki Y, Chen J J, Iribe H, Fuji H, Köhler H. Tumor specific idiotype vaccines. 11. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2B). J Immunol 1987; 139: 271–278
   PubMed Web of Science ®Google Scholar